EICHORPublic-registry site landscape for NCT07750158, “Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease”, a Colorectal Cancer study sponsored by Exelixis. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07750158 (registry record) |
| Study title | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease |
| Official title | Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy |
| Sponsor | Exelixis |
| Condition(s) | Colorectal Cancer |
| Phase | PHASE3 |
| Listed sites | 0 |
| Intervention(s) | Zanzalintinib, MK-34574, Placebo |
Patient-friendly overview of this study: eichor.com/study/NCT07750158.
Eichor generates a preliminary site-risk snapshot for NCT07750158 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
